Cardiac effects of 5F-Cumyl-PEGACLONE
Authors:
Open Access
- 12 January 2024
- journal article
- research article
- Published by Springer Nature in International journal of legal medicine
- Vol. 138 (3) , 823-831
Abstract
Synthetic cannabinoids become increasingly popular as a supposedly safe and legal alternative to cannabis. In order to circumvent the German New Psychoactive Substances Law, producers of so-called herbal mixtures rapidly design new substances with structural alterations that are not covered by the law. Acting as full agonists not only at the cannabinoid receptors 1 and 2, synthetic cannabinoids might have not only desired mental but also serious physical adverse effects. However, knowledge of adverse effects of specific substances is sparse and incomplete. This also accounts for 5F-Cumyl-PEGACLONE, a synthetic cannabinoid, which has been detected regularly in Germany in recent years. By using an animal model, the isolated perfused Langendorff heart, the study at hand aimed on finding out more about possible cardiovascular adverse effects of 5F-Cumyl-PEGACLONE. Hearts of male Wistar rats, which were excised postmortem, were exposed to two different concentrations of 5F-Cumyl-PEGACLONE: 13 hearts were exposed to 50 ng/ml and 12 hearts were exposed to 100 ng/ml. Thirteen control hearts were merely exposed to an additional amount of buffer solution. Functional parameters heart rate, minimal and maximum left ventricular pressure and coronary flow were documented at pre-defined time points during and after the administration of 5F-Cumyl-PEGACLONE/additional buffer solution. Electrocardiograms (ECGs) were documented throughout the experiments and evaluated afterwards. Kruskal–Wallis analysis was performed for each functional parameter as well as for the duration of the QRS complexes and the duration of RR intervals as derived from the ECGs. Furthermore, a multivariate analysis, comprising all functional and ECG parameters, was performed. Kruskal–Wallis analysis revealed only single significant p-values for QRS duration and minimum left ventricular pressure that did not pass a Bonferroni test. The results of the multivariate approach were also comparably homogeneous, but still the model correctly recognized hearts exposed to 100 ng/ml of 5F-Cumyl-PEGACLONE more often than hearts exposed to the low concentration of 5F-Cumyl-PEGACLONE or additional buffer solution. Evaluation of the ECGs presented single cases of ST depression and QT prolongation. Though certainly not unambiguous, these findings support the assumption that 5F-Cumyl-PEGACLONE can cause severe, if not lethal, cardiac adverse effects like arrhythmias or myocardial infarctions especially if it is consumed in combination with other drugs like alcohol or if the consumer suffers from pre-existing heart diseases.Keywords
Funding Information
- Universitätsklinikum Düsseldorf. Anstalt öffentlichen Rechts
This publication has 30 references indexed in Scilit:
- The behavioral profile of spice and synthetic cannabinoids in humansBrain Research Bulletin, 2016
- Synthetic Cannabinoids and Their Effects on the Cardiovascular SystemThe Journal of Emergency Medicine, 2016
- Synthetic CannabinoidsThe American Journal of the Medical Sciences, 2015
- Effects of Bioisosteric Fluorine in Synthetic Cannabinoid Designer Drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135ACS Chemical Neuroscience, 2015
- Inhomogeneities in herbal mixtures: a serious risk for consumersForensic Toxicology, 2014
- Spicing things up: synthetic cannabinoidsPsychopharmacology, 2013
- Simultaneous analysis of synthetic cannabinoids in the materials seized during drug trafficking using GC-MSAnalytical and Bioanalytical Chemistry, 2012
- Analysis of First and Second Generation Legal Highs for Synthetic Cannabinoids and Synthetic Stimulants by Ultra-Performance Liquid Chromatography and Time of Flight Mass SpectrometryJournal of Analytical Toxicology, 2012
- Spice: A never ending story?Forensic Science International, 2009
- The complexities of the cardiovascular actions of cannabinoidsBritish Journal of Pharmacology, 2004